<DOC>
	<DOCNO>NCT02511613</DOCNO>
	<brief_summary>The purpose study evaluate anatomical functional effect combination therapy Squalamine Lactate Ophthalmic Solution , 0.2 % administered twice daily monthly ranibizumab intravitreal injection patient choroidal neovascularization due AMD .</brief_summary>
	<brief_title>Effect Squalamine Lactate Ophthalmic Solution , 0.2 % Subjects With Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description>Subjects age-related macular degeneration meet inclusion exclusion criterion randomize receive monthly intravitreal injection ranibizumab ( Lucentis® ) either Squalamine Lactate Ophthalmic solution 0.2 % placebo eye drop twice day 6 month . Subjects evaluate clinical imaging technique .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Squalamine</mesh_term>
	<criteria>50 year age old A diagnosis choroidal neovascularization secondary agerelated macular degeneration ( AMD ) choroidal neovascularization ( CNV ) comprise least 50 % total lesion area study eye Central retinal thickness ≥ 300 μm presence subretinal fluid cystoid edema Optical Coherence Tomography ( OCT ) Best Corrected Visual Acuity ( BCVA ) 20/40 20/320 Early Treatment Diabetic Retinopathy Study ( ETDRS ) Protocol Neovascularization secondary condition AMD study eye Blood occupy great 50 % AMD lesion , blood &gt; 1.0 sq . mm underlie fovea PED without associate subretinal fluid and/or cystic retinal change Clinical evidence diabetic retinopathy diabetic macular edema study eye Confounding ocular condition study eye affect interpretation OCT , VA assessment macular appearance ( e.g. , cataract , epiretinal membrane , retinal vascular occlusive disease ) Fibrosis atrophy , retinal epithelial tear center fovea study eye condition prevent VA improvement Uncontrolled glaucoma study eye , currently receive topical glaucoma medication study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>